

6

10.04.2000

Claims

(41)

1. Paroxetine methanesulfonate in crystalline form having a melting point in the range 145 to 148°C.
- 5 2. A compound according to claim 1 having a melting point of 145 to 146°C.
3. A compound according to claim 1 having a melting point of 146 to 148°C.
- 10 4. A compound according to claim 1 having a melting point of 147 to 148°C.
5. A process for the preparation of a compound as claimed in any one of claims 1 to 4 comprising crystallizing or re-crystallizing the compound from a solution of paroxetine methanesulfonate in a solvent.
- 15 6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.
7. A composition according to claim 6 in which the carrier comprises a disintegrant.
- 20 8. A composition according to claim 6 or 7 which is a tablet or capsule.
9. A composition according to any one of claims 6 to 8 which comprises 10, 12.5, 15, 20, 25, 30 or 40mg of paroxetine methanesulfonate per unit dose, calculated on a free base basis.
- 25 10. Use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament for use in the treatment and/or prevention of any one or more of the Disorders.
- 30

10. 01. 2000

ABSTRACT

(47)

NOVEL COMPOUND

- 5 Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.